ArticleFrontiers in medicine2026
Efficacy and factors associated with reactivation following intravitreal ranibizumab or conbercept for retinopathy of prematurity.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To compare the efficacy of intravitreal ranibizumab (IVR) and conbercept (IVC) treatment for retinopathy of prematurity (ROP) and to evaluate the risk factors associated with disease reactivation. Methods: In this retrospective study, the medical records of infants with ROP treated with IVR or IVC from April 2017 to June 2024 at Guangdong Women and Children Hospital were reviewed. The primary outcome measures were reactivation rate, time to reactivation, and factors associated with reactivation. Results: A total of 294 infants (565 eyes) were included. The reactivation rate was 10.39% (43 of 414 eyes) in the IVR group and 12.58% (19 of 151 eyes) in the IVC group, with no significant difference between the two groups ( Conclusion: Ranibizumab and conbercept are effective for treating ROP. A lower PMA at initial treatment and Zone I ROP were identified as significant risk factors for reactivation. Infants with these characteristics require closer and more prolonged follow-up after anti-VEGF therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.